BREAKTHROUGH NATURAL SUPPORT FOR:1. ITCHING CAUSED BY A SENSITIVITY TO ENVIRONMENTAL ALLERGENS2. JOINT RELIEF3. COGNITIVE HEALTH MICRONISED FOR OPTIMUM POTENCYONLY FORM FORMULATED SPECIFICALLY FOR ANIMALS TO ENSURE MAXIMUM BENEFITSNO FILLERS, BINDERS, GLUES OR CHEMICAL ADDITIVES OF ANY KIND.Click here to read 'PEA FACTSHEET'.SENSITIVITY TO ENVIRONMENTAL ALLERGENSClick here to read 'How is atopy diagnosed?' Click here to read 'An Itchy Skin - A Simple Approach.'Click here to read 'What if my pet is already on medication for Itching?'Monitor progress using our handy record card (supplied with each bottle purchased.)NOTEAllow PEA 12 weeks to reach peak effect before gauging its effect. JOINTS STIFFNESS AND PAIN MANAGEMENTClick here to read about 'Ultimate Joint Support - How to avoid non-steroidal anti-inflammatories (NSAID's) and Librela.'Monitor progress using our handy record card (supplied with each bottle purchased.)NOTEAllow PEA 12 weeks to reach peak effect before gauging its effect. Clinical Studies in Animals and Humans ITCHY SKINEfficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre studySummary: 66% of dogs benefited from micronised PEA supplementation, in terms of reduced itching and improved quality of life after 8 weeks.JOINT HEALTHChronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?Summary: Supplementation with micronised PEA shows promise for managing chronic pain, including joint pain, in dogs, cats and horses.Oral Supplementation with Ultramicronised Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case ReportSummary: BRAIN AND COGNITIVE FUNCTIONSuccessful and Unsuccessful Brain Aging in PetsSummary: In various in vitro and animal models of neurodegenerative conditions and senile dementia, PEA exhibits anti-inflammatory and neuroprotective effects, and supports improved cognitive performance in elderly animals.PAIN MANAGEMENTA double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis (in humans)Summary: The study assessed the safety, tolerability, and efficacy of palmitoylethanolamide (PEA) in 111 adults with mild to moderate knee osteoarthritis. Improvements were seen in all measured outcomes (joint pain, stiffness, and function) using the WOMAC sub-domains, suggesting that PEA is effective in reducing symptoms of knee osteoarthritis and improving quality of life. (Vince the Vet PEA is human food grade quality.)Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different EtiopathogenesisSummary: The study on palmitoylethanolamide (PEA) included a total of 610 participants who were suffering from various chronic pain conditions involving nerves, muscles, joints and other parts of the body. Also see:NOTEAllow PEA 12 weeks to reach peak effect before gauging its effect.
£33.00
